Over-The-Counter Vitamin-Like Substance In High Doses May Slow Parkinson’s Progress

In a large-scale clinical trial, researchers are trying to find out if an over-the-counter vitamin-like substance, in high doses, can slow the progression of Parkinson's disease.

The clinical trial is being done by researchers at Rush University Medical Center.

Parkinson’s Disease - Causes, Symptoms, Diagnosis, Treatment
Parkinson’s disease is a neurodegenerative disease caused by progressive dopamine brain cells loss. Symptoms of Parkinson’s disease are correctable to an extent.

The substance being tested, called coenzyme Q10, is produced naturally in the body and is an important link in the chain of chemical reactions that produce energy in mitochondria, the "powerhouses" of cells.

The enzyme is also a potent antioxidant - a chemical that "mops up" potentially harmful chemicals generated during normal metabolism.

"At present, the very best therapies we have for Parkinson's can only mask the symptoms - they do not alter the underlying disease. Finding a treatment that can slow the degenerative course of Parkinsons's is the holy grail of Parkinson's research," said neurologist Dr. Katie Kompoliti, a specialist in movement disorders.

Occupational Proximity And Pesticide Exposure May Increase Parkinson's Risk
People whose jobs involve regular pesticide exposure may be more prone to Parkinson's disease, finds a new study.

Many past studies have shown that Parkinson's patients have impaired mitochondrial function and low levels of coenzyme Q10.

Moreover, laboratory research has demonstrated that coenzyme Q10 can protect the area of the brain damaged in Parkinson's.

Novel Therapeutic Target for Parkinson's Disease Identified
Scientists from University of Helsinki Institute of Biotechnology have identified a novel therapeutic target for Parkinson's disease.

The Phase III clinical trial, a large, randomized study with a control group, follows an earlier investigation that tested several doses of coenzyme Q10 in a small group of patients with early-stage Parkinson's disease.

The highest dose, 1,200 mg, appeared promising-over the course of 16 months, patients taking this dose experienced significantly less decline than other patients in motor (movement) function and ability to carry out activities of daily living, such as feeding or dressing themselves.

In the present trial, 600 patients will be enrolled at 60 centers in the U.S. and Canada.

Two dosages of coenzyme Q10 are being tested,1,200 mg and 2,400 mg, delivered in maple nut-flavored chewable wafers that also contain vitamin E.

Participants in the study will be evaluated periodically over 16 months for symptoms of Parkinson's disease, including tremor, stiffness of the limbs and trunk, impaired balance and coordination, and slowing of movements.

They will also be assessed for ability to perform daily activities, overall quality of life, and need to take medications to alleviate symptoms.

Source-ANI
ARU